Anti-Human IL31RA Therapeutic Antibody (Nemolizumab) (CAT#: TAB-439CQ)

Recombinant monoclonal antibody to IL31RA. Nemolizumab is a humanized monoclonal antibody that can be potentially used in the treatment of Atopic dermatitis, Pruritus.

Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Published Data
  • Datasheet
  • MSDS
  • COA

Figure 1 Percentage reduction from baseline Owner Pruritus Visual Analog Scale (VAS) score (±SE) following subcutaneous administration of placebo or lokivetmab once on Day 0. See for number of dogs on study per treatment group at each day of study.

(A) BaF/2C6/16 cells (7.5×103/well) were cultured in 96‐well plates in RPMI‐1640 medium supplemented with 10% FBS and 100 units/mL penicillin‐100 μg/mL streptomycin and with or without hIL‐31 (0.3 ng/mL) in the presence of the indicated concentrations of nemolizumab. (B) BaF/cyIL‐31R cells (7.5×103/well) were cultured with or without cyIL‐31 (1 ng/mL) in the presence of the indicated concentrations of nemolizumab. Cell proliferation was evaluated by measuring the absorbance at 450/620 nm. (C) hIL‐31 (30 ng/mL)‐induced STAT3 phosphorylation in the presence of the various concentrations of nemolizumab in A549 cells (4×105 cells/well) was evaluated by measuring the absorbance at 450 nm as an indicator of the phosphorylation. (D‐F) Production of hIL‐31‐induced IL‐6, MMP‐1 and MMP‐3 in HaCaT cells (1×104 cells/well) in the presence of 100 ng/mL IFN‐γ was analysed by using a human IL‐6, MMP‐1 or MMP‐3 Quantikine ELISA Kit (R&D Systems). Data are expressed as the mean+SD (n=3).

Oyama, S. , Kitamura, H. , Kuramochi, T. , Higuchi, Y. , Matsushita, H. , & Suzuki, T. , et al. (2016). Cynomolgus monkey model of interleukin-31-induced scratching depicts blockade of human interleukin-31 receptor a by a humanized monoclonal antibody. Experimental Dermatology.

Figure 2 Inhibition of IL‐31‐induced scratching by nemolizumab (CIM331) in cynomolgus monkeys.

To examine the inhibitory effect of nemolizumab, the antibody was intravenously or subcutaneously administered to animals. (A) Plasma nemolizumab concentration after intravenous injection in monkey. Nemolizumab was administered to animals on Days 0 (vehicle only), 2, 7, 9, 14 and 16, as indicated by arrows. Plasma nemolizumab concentration was measured (limit of quantification: 8.00 ng/mL) on Days 3, 8, 9, 10, 14, 15, 16 and 17. Data are expressed as the mean±SEM (n=6), but bars depicting SEM are smaller than the symbols. (B) Scratching movements were counted from video recordings taken for 2 h on Days 0, 1, 3, 8, 10, 15 and 17 of monkeys that had been intravenously injected with ascending doses of nemolizumab or with vehicle (see times indicated by arrows, vehicle also given on Day 0) and then dosed with an intravenous injection of cyIL‐31 (circles) the day after. Squares denote counts from recordings taken on Days 0 (squares overlap) and 16 of monkeys that were injected with nemolizumab or vehicle but not injected with cyIL‐31. Data are expressed as mean±SEM (n=4 (vehicle), n=6 (CIM331)). (C) Nemolizumab plasma concentration‐response curve for percentage of initial scratching count on Day 1 and plasma nemolizumab concentration of nemolizumab‐treated animals at all time points. (D) Inhibition of IL‐31‐induced scratching by subcutaneously administered nemolizumab was evaluated in cynomolgus monkeys. Vehicle or 1 mg/kg of nemolizumab was administered subcutaneously to cynomolgus monkeys on Day 0. The cyIL‐31‐induced scratching was evaluated on Days −1, 28 and 56, and the basal scratching was counted on Day −2. Video‐recorded scratching behaviours were counted under a blinded manner. Data are expressed as the mean+SEM (n=6, except for the CIM331 group on Day 56 (n=5)). *P<0.05.

Oyama, S. , Kitamura, H. , Kuramochi, T. , Higuchi, Y. , Matsushita, H. , & Suzuki, T. , et al. (2016). Cynomolgus monkey model of interleukin-31-induced scratching depicts blockade of human interleukin-31 receptor a by a humanized monoclonal antibody. Experimental Dermatology.


Specifications

  • Immunogen
  • The details of the immunogen for this antibody are not available.
  • Host Species
  • Human
  • Derivation
  • Humanized
  • Type
  • IgG2, κ
  • Specificity
  • Human IL31RA
  • Species Reactivity
  • Human
  • Applications
  • ELISA, IHC, FC, IP, IF, FuncS
  • Conjugate
  • Unconjugated
  • CAS
  • 1476039-58-3
  • Generic Name
  • Nemolizumab
  • UNII
  • GN465U8B72
  • Related Disease
  • Atopic dermatitis, Pruritus

Applications

  • Application Notes
  • The IL31RA antibody has been reported in applications of Neut, Inhib.
    Inhibition: To investigate the inhibition of native IL‐31 signalling by nemolizumab, A549 cells (ATCC, Virginia, USA) were cultured in F‐12K medium (Life Technologies, Tokyo, Japan) containing 10% foetal bovine serum (FBS) and 100 units/mL penicillin‐100 μg/mL streptomycin in 24‐well plates) overnight. Next, the cells were treated with nemolizumab for 2 hours and then hIL‐31 was added. After incubation for 20 minutes, cells were lysed and the phosphorylation of STAT3 was analysed with the PathScan Phospho‐Stat3 (Tyr705) Sandwich ELISA Kit.

Target

  • Alternative Names
  • CRL; GPL; CRL3; GLMR; GLM-R; PLCA2; hGLM-R; IL-31RA; PRO21384

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Resources

Please click here for more details about the introduction to mechanism of action, clinical projects and approved drugs of Nemolizumab.

See other products for "Nemolizumab"

Afuco™ Anti-IL31RA ADCC Therapeutic Antibody (Nemolizumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to IL31RA. Nemolizumab is a humanized monoclonal antibody that can be potentially used in the treatment of Atopic dermatitis, Pruritus.

See other products for "IL31RA"


For research use only. Not intended for any clinical use.

* Abbreviations
3D IHC3D Immunohistochemistry
ActivActivation
AgonistAgonist
ApopApoptosis
BABioassay
BIBioimaging
BlockBlocking
Cell ScreeningCell Screening
SeparationCell Separation
ChIPChromatin Immunoprecipitation
CMCDComplement Mediated Cell Depletion
CostimCostimulation
CytCytotoxicity
DepletionDepletion
DBDot Blot
EMElectron Microscopy
ELISAEnzyme-linked Immunosorbent Assay
ELISPOTEnzyme-linked Immunosorbent Spot
FCFlow Cytometry
FuncSFunctional Assay
GSGel Super Shift Assay
HAHemagglutination
IAImmunoassay
IBImmunoblotting
ICCImmunocytochemistry
IDImmunodiffusion
IFImmunofluorescence
IHCImmunohistochemistry
IHC-FrImmunohistochemistry-Frozen
IHC-PImmunohistochemistry-Paraffin
REImmunohistology - Resin Sections
IPImmunoprecipitation
IRMAImmunoradiometric Assay
SHIn situ hybridization
InhibInhibition
ICFCIntracellular Staining for Flow Cytometry
KO/KD-WBKnockout/Knockdown target confirmation by Western Blot
Live cell imagingLive cell imaging
CyTOF®Mass Cytometry
MeDIPMethylated DNA Immunoprecipitation
MultiplexMultiplex bead-based assay
NeutNeutralization
PPProtein Purification
PGProteogenomics
RIRadial Immunodiffusion
RIARadioimmunoassay
StimStimulation
SPRSurface Plasmon Resonance
TCTissue Culture
TBTurbidimetry
WBWestern Blot

Send Inquiry

  • Verification code
    Click image to refresh the verification code.
© 2007 - 2020 Creative BioLabs All Rights Reserved
  • 0
  • 0

Cart